MAGGIE SMITH: Open Payments
NPI 1134584295 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,106 in 56 payments from 19 companies in 2025. Trend: 2023 $1,070 · 2024 $854 · 2025 $1,106
Food & beverage: $1,106
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $239 |
| GlaxoSmithKline, LLC. | 8 | $165 |
| Novo Nordisk Inc | 5 | $94 |
| Lilly USA, LLC | 5 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Boston Scientific Corporation | 1 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Antares Pharma, Inc. | 2 | $37 |
Products named: VRAYLAR, SHINGRIX, QULIPTA, Ozempic, CAPLYTA, MOUNJARO, TRELEGY ELLIPTA, Auvelity.
Industry payments across LA — which companies pay providers there.
